• Subscribe
  • Newsfeed
  • About
  • Jobs
Announce News

Acadian Ventures

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

    Origin raises a £22m Series A+ led by Notion Capital for enterprise benefits intelligence platformOrigin raises a £22m Series A+ led by Notion Capital for enterprise benefits intelligence platform
    Origin
    25 Mar 2026

    Origin raises a £22m Series A+ led by Notion Capital for enterprise benefits intelligence platform

    Origin is a platform that helps large organisations manage and understand their global employee benefits. It brings fragmented benefits data into one system so companies can track spend, identify inefficiencies and improve employee experience.

    Origin lands £16m Series A from Felix Capital to launch AI-powered benefits intelligence platformOrigin lands £16m Series A from Felix Capital to launch AI-powered benefits intelligence platform
    Origin
    14 May 2025

    Origin lands £16m Series A from Felix Capital to launch AI-powered benefits intelligence platform

    Origin builds an AI-powered benefits intelligence platform that helps multinational employers understand, manage and optimise employee benefits spend using structured insights from fragmented global data.

Acadian Ventures
    • HR
  • 2(12 months)
  • acadianventures.com
  • Update Information

More venture news

  • Origin raises a £22m Series A+ led by Notion Capital for enterprise benefits intelligence platform
    Origin
    25 Mar 2026

    Origin raises a £22m Series A+ led by Notion Capital for enterprise benefits intelligence platform

    ExtensionHR
  • Brainomix lands a £4.8m Series C extension led by Parkwalk Advisors and Hostplus for AI medical imaging in stroke and lung fibrosis
    Brainomix
    24 Feb 2026

    Brainomix lands a £4.8m Series C extension led by Parkwalk Advisors and Hostplus for AI medical imaging in stroke and lung fibrosis

    ExtensionHealth
  • Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy
    Centauri Therapeutics
    24 Feb 2026

    Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy

    ExtensionLife Sciences

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn